Loading...

Tristel

AIM:TSTL
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TSTL
AIM
£137M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Tristel Plc develops, manufactures, and supplies infection and contamination control, and hygiene products in the United Kingdom, Germany, and internationally. The last earnings update was 86 days ago. More info.


Add to Portfolio Compare Print
TSTL Share Price and Events
7 Day Returns
-1.6%
AIM:TSTL
-0%
GB Medical Equipment
1%
GB Market
1 Year Returns
-3.2%
AIM:TSTL
5.1%
GB Medical Equipment
-6.3%
GB Market
TSTL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Tristel (TSTL) -1.6% -0.8% 1.7% -3.2% 162.8% 321.2%
GB Medical Equipment -0% 10.2% 12% 5.1% 38.9% 62.4%
GB Market 1% -1.8% 1.5% -6.3% 14.4% 2%
1 Year Return vs Industry and Market
  • TSTL underperformed the Medical Equipment industry which returned 5.1% over the past year.
  • TSTL outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -6.3% over the past year.
Price Volatility
TSTL
Industry
5yr Volatility vs Market

Value

 Is Tristel undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Tristel to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Tristel.

AIM:TSTL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.4%
Perpetual Growth Rate 10-Year GB Government Bond Rate 1.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for AIM:TSTL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 1.2%
Equity Risk Premium S&P Global 6.7%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.9
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.895 (1 + (1- 19%) (0%))
0.93
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.23% + (0.93 * 6.65%)
7.41%

Discounted Cash Flow Calculation for AIM:TSTL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Tristel is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

AIM:TSTL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 7.41%)
2019 4.00 Analyst x1 3.72
2020 5.50 Analyst x1 4.77
2021 6.25 Est @ 13.69% 5.05
2022 6.88 Est @ 9.95% 5.17
2023 7.38 Est @ 7.33% 5.16
2024 7.79 Est @ 5.5% 5.07
2025 8.11 Est @ 4.22% 4.92
2026 8.38 Est @ 3.32% 4.73
2027 8.61 Est @ 2.69% 4.52
2028 8.80 Est @ 2.25% 4.31
Present value of next 10 years cash flows £47.42
AIM:TSTL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= £8.80 × (1 + 1.23%) ÷ (7.41% – 1.23%)
£144.12
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £144.12 ÷ (1 + 7.41%)10
£70.51
AIM:TSTL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £47.42 + £70.51
£117.93
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £117.93 / 44.51
£2.65
AIM:TSTL Discount to Share Price
Calculation Result
Value per share (GBP) From above. £2.65
Current discount Discount to share price of £3.08
= -1 x (£3.08 - £2.65) / £2.65
-16.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Tristel is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Tristel's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Tristel's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:TSTL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in GBP £0.08
AIM:TSTL Share Price ** AIM (2019-05-22) in GBP £3.08
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 10 Publicly-Listed Medical Equipment Companies 27.92x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 788 Publicly-Listed Companies 16.35x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Tristel.

AIM:TSTL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:TSTL Share Price ÷ EPS (both in GBP)

= 3.08 ÷ 0.08

38.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tristel is overvalued based on earnings compared to the GB Medical Equipment industry average.
  • Tristel is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Tristel's expected growth come at a high price?
Raw Data
AIM:TSTL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 38.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
21%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 1.54x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 574 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

AIM:TSTL PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 38.21x ÷ 21%

1.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tristel is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Tristel's assets?
Raw Data
AIM:TSTL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in GBP £0.47
AIM:TSTL Share Price * AIM (2019-05-22) in GBP £3.08
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.51x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,369 Publicly-Listed Companies 1.51x
AIM:TSTL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:TSTL Share Price ÷ Book Value per Share (both in GBP)

= 3.08 ÷ 0.47

6.51x

* Primary Listing of Tristel.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tristel is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Tristel's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Tristel has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Tristel expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Tristel expected to grow at an attractive rate?
  • Tristel's earnings growth is expected to exceed the low risk savings rate of 1.2%.
Growth vs Market Checks
  • Tristel's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Tristel's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
AIM:TSTL Future Growth Rates Data Sources
Data Point Source Value (per year)
AIM:TSTL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 21%
AIM:TSTL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 14.9%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 8.2%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 11%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:TSTL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:TSTL Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-06-30 29 8 5 1
2019-06-30 26 6 4 1
AIM:TSTL Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-12-31 24 6 3
2018-09-30 23 5 3
2018-06-30 22 4 3
2018-03-31 22 4 3
2017-12-31 21 4 4
2017-09-30 21 4 3
2017-06-30 20 4 3
2017-03-31 20 4 3
2016-12-31 19 4 3
2016-09-30 18 4 3
2016-06-30 17 5 2
2016-03-31 17 4 2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Tristel's earnings are expected to grow significantly at over 20% yearly.
  • Tristel's revenue is expected to grow by 14.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:TSTL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Tristel Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:TSTL Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-06-30 0.11 0.11 0.11 1.00
2019-06-30 0.09 0.09 0.09 1.00
AIM:TSTL Past Financials Data
Date (Data in GBP Millions) EPS *
2018-12-31 0.08
2018-09-30 0.08
2018-06-30 0.08
2018-03-31 0.08
2017-12-31 0.08
2017-09-30 0.08
2017-06-30 0.08
2017-03-31 0.08
2016-12-31 0.08
2016-09-30 0.06
2016-06-30 0.05
2016-03-31 0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Tristel will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Tristel's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Tristel has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Tristel performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Tristel's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Tristel has delivered over 20% year on year earnings growth in the past 5 years.
  • Tristel's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Tristel's 1-year earnings growth is negative, it can't be compared to the GB Medical Equipment industry average.
Earnings and Revenue History
Tristel's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Tristel Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:TSTL Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 23.51 3.49 12.55
2018-09-30 22.87 3.38 12.09
2018-06-30 22.22 3.27 11.64
2018-03-31 21.74 3.43 11.30
2017-12-31 21.25 3.58 10.97
2017-09-30 20.76 3.50 10.69
2017-06-30 20.27 3.42 10.40
2017-03-31 19.56 3.36 9.71
2016-12-31 18.84 3.30 9.02
2016-09-30 17.97 2.70 8.97
2016-06-30 17.10 2.10 8.92
2016-03-31 16.52 1.87 8.70
2015-12-31 15.93 1.63 8.47
2015-09-30 15.63 1.92 7.88
2015-06-30 15.33 2.22 7.28
2015-03-31 14.89 1.94 7.16
2014-12-31 14.44 1.66 7.05
2014-09-30 13.96 1.48 6.87
2014-06-30 13.47 1.30 6.70
2014-03-31 13.03 1.15 6.34
2013-12-31 12.60 1.00 5.98
2013-09-30 11.58 -0.13 5.75
2013-06-30 10.56 -1.26 5.53
2013-03-31 10.42 -1.48 5.63
2012-12-31 10.28 -1.69 5.72
2012-09-30 10.61 -0.49 5.67
2012-06-30 10.94 0.71 5.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Tristel has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Tristel used its assets more efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Tristel has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Tristel's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Tristel has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Tristel's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Tristel's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Tristel is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Tristel's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Tristel's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Tristel has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Tristel Company Filings, last reported 4 months ago.

AIM:TSTL Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 20.69 0.00 4.49
2018-09-30 20.69 0.00 4.49
2018-06-30 18.43 0.00 6.66
2018-03-31 18.43 0.00 6.66
2017-12-31 16.84 0.00 4.95
2017-09-30 16.84 0.00 4.95
2017-06-30 16.06 0.00 5.09
2017-03-31 16.06 0.00 5.09
2016-12-31 14.28 0.00 3.85
2016-09-30 14.28 0.00 3.85
2016-06-30 14.96 0.00 5.72
2016-03-31 14.96 0.00 5.72
2015-12-31 13.79 0.00 4.26
2015-09-30 13.79 0.00 4.26
2015-06-30 14.17 0.00 4.05
2015-03-31 14.17 0.00 4.05
2014-12-31 12.63 0.03 2.95
2014-09-30 12.63 0.03 2.95
2014-06-30 12.08 0.05 2.66
2014-03-31 12.08 0.05 2.66
2013-12-31 11.37 0.08 1.62
2013-09-30 11.37 0.08 1.62
2013-06-30 10.88 0.12 0.63
2013-03-31 10.88 0.12 0.63
2012-12-31 10.43 0.35
2012-09-30 10.43 0.35
2012-06-30 12.41 0.17 0.71
  • Tristel has no debt.
  • Tristel has no debt compared to 5 years ago when it was 0.7%.
  • Tristel has no debt, it does not need to be covered by operating cash flow.
  • Tristel has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Tristel's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Tristel has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Tristel's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.49%
Current annual income from Tristel dividends. Estimated to be 1.87% next year.
If you bought £2,000 of Tristel shares you are expected to receive £30 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Tristel's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (1.97%).
  • Tristel's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (5.25%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:TSTL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 6 Stocks 1.9%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 706 Stocks 4.3%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:TSTL Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2020-06-30 0.06 1.00
2019-06-30 0.05 1.00
AIM:TSTL Past Annualized Dividends Data
Date (Data in £) Dividend per share (annual) Avg. Yield (%)
2018-12-10 0.046 1.597
2017-10-19 0.040 1.464
2016-10-17 0.063 3.256
2016-08-30 0.063 4.335
2015-10-12 0.027 2.226
2014-12-01 0.025 2.953
2013-10-15 0.004 0.743
2013-10-14 0.004 1.511
2013-03-04 0.004 1.825
2012-10-30 0.006 2.033
2012-10-29 0.006 1.648
2011-10-24 0.006 1.583
2010-10-18 0.018 3.631
2010-10-15 0.018 3.245
2009-10-12 0.017 3.052
2009-10-09 0.017 3.257

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Tristel's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.6x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Tristel's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Tristel afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Tristel has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Tristel's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Swinney
COMPENSATION £324,000
AGE 59
TENURE AS CEO 26.3 years
CEO Bio

Mr. Paul C. Swinney serves as the Chief Executive Officer of Tristel Plc. since 1993 and serves as its Director. Mr. Swinney started his career with Brown, Shipley & Co in 1980. He worked for the European banking operations of Norwest Bank Minneapolis and Maryland National Bank, before joining OSI Finance, a specialist in shipping finance, in 1987. In 1993 he co-founded the business that was to become Tristel plc.

CEO Compensation
  • Paul's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Paul's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Tristel management team in years:

8.9
Average Tenure
55
Average Age
  • The average tenure for the Tristel management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Paul Swinney

TITLE
CEO & Executive Director
COMPENSATION
£324K
AGE
59
TENURE
26.3 yrs

Liz Dixon

TITLE
Finance Director
COMPENSATION
£589K
AGE
48
TENURE
8.9 yrs

Bart Margaretha Leemans

TITLE
Executive Director
AGE
55
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the Tristel board of directors in years:

0.4
Average Tenure
57
Average Age
  • The average tenure for the Tristel board of directors is less than 3 years, this suggests a new board.
Board of Directors

Paul Barnes

TITLE
Interim Non-Executive Chairman
COMPENSATION
£35K
AGE
65
TENURE
0.4 yrs

Paul Swinney

TITLE
CEO & Executive Director
COMPENSATION
£324K
AGE
59

Liz Dixon

TITLE
Finance Director
COMPENSATION
£589K
AGE
48

Bart Margaretha Leemans

TITLE
Executive Director
AGE
55
TENURE
0.5 yrs

David William Orr

TITLE
Non-Executive Director
COMPENSATION
£35K
AGE
59
TENURE
3.6 yrs

Tom Arthur Jenkins

TITLE
Senior Independent Non-Executive Director
COMPENSATION
£25K
AGE
46
TENURE
0.3 yrs

Bruno Luc Holthof

TITLE
Independent Non-Executive Director
AGE
57
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • Tristel insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
04. Mar 19 Buy Bart Margaretha Leemans Individual 04. Mar 19 04. Mar 19 135,915 £2.43 £329,866
01. Mar 19 Sell Bart Margaretha Leemans Individual 28. Feb 19 28. Feb 19 -280,000 £2.99 £-837,200
11. Jun 18 Sell Paul Barnes Individual 08. Jun 18 08. Jun 18 -15,000 £3.13 £-46,875
01. Jun 18 Buy David William Orr Individual 31. May 18 31. May 18 7,000 £3.06 £21,424
01. Jun 18 Sell Francisco Soler Individual 30. May 18 30. May 18 -50,000 £3.01 £-150,250
X
Management checks
We assess Tristel's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Tristel has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Tristel Plc’s (LON:TSTL) 21% ROCE Any Good?

What is Return On Capital Employed (ROCE)? … Analysts use this formula to calculate return on capital employed: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) Or for Tristel: 0.21 = UK£4.4m ÷ (UK£27m - UK£6.0m) (Based on the trailing twelve months to December 2018.) So, Tristel has an ROCE of 21%. … Our Take On Tristel's ROCE Low current liabilities and high ROCE is a good combination, making Tristel look quite interesting.

Simply Wall St -

Have Insiders Been Selling Tristel Plc (LON:TSTL) Shares This Year?

We often see insiders buying up shares in companies that perform well over the long term. … So shareholders might well want to know whether insiders have been buying or selling shares in Tristel Plc (LON:TSTL). … But logic dictates you should pay some attention to whether insiders are buying or selling shares.

Simply Wall St -

Should You Worry About Tristel Plc's (LON:TSTL) CEO Pay Cheque?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Paul Swinney's Compensation Compare With Similar Sized Companies. … Our data indicates that Tristel Plc is worth UK£137m, and total annual CEO compensation is UK£324k.

Simply Wall St -

Is Tristel Plc (LON:TSTL) An Attractive Dividend Stock?

Yet sometimes, investors buy a stock for its dividend and lose money because the share price falls by more than they earned in dividend payments. … When buying stocks for their dividends, you should always run through the checks below, to see if the dividend looks sustainable. … AIM:TSTL Historical Dividend Yield, April 17th 2019

Simply Wall St -

Should You Be Concerned About Tristel Plc's (LON:TSTL) Historical Volatility?

Volatility is considered to be a measure of risk in modern finance theory. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

When Should You Buy Tristel Plc (LON:TSTL)?

saw a double-digit share price rise of over 10% in the past couple of months on the AIM. … Less-covered, small caps sees more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing? … So, could the stock still be trading at a low price relative to its actual value.

Simply Wall St -

Did You Miss Tristel's Whopping 522% Share Price Gain?

One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … During five years of share price growth, Tristel achieved compound earnings per share (EPS) growth of 26% per year. … This EPS growth is slower than the share price growth of 44% per year, over the same period.

Simply Wall St -

What Does Tristel Plc's (LON:TSTL) P/E Ratio Tell You?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … We'll look at Tristel Plc's (LON:TSTL) P/E ratio and reflect on what it tells us about the company's share price. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

Tristel Plc (LON:TSTL): Time For A Financial Health Check

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does TSTL's growth rate justify its decision for financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

An Examination Of Tristel Plc (LON:TSTL)

As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … financial health as well as

Simply Wall St -

Company Info

Description

Tristel Plc develops, manufactures, and supplies infection and contamination control, and hygiene products in the United Kingdom, Germany, and internationally. The company operates through three segments: Human Healthcare, Animal Healthcare, and Contamination Control. It offers hospital infection prevention and control products under the Tristel brand; contamination control products for pharmaceutical and personal care industries under the Crystel brand; and animal health infection prevention and control products under the Anistel brand. Tristel Plc was founded in 1993 and is based in Snailwell, the United Kingdom.

Details
Name: Tristel Plc
TSTL
Exchange: AIM
Founded: 1993
£136,867,705
44,509,823
Website: http://www.tristel.com
Address: Tristel Plc
Lynx Business Park,
Unit 1B,
Snailwell,
Cambridgeshire, CB8 7NY,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM TSTL Ordinary Shares London Stock Exchange AIM Market GB GBP 01. Jun 2005
Number of employees
Current staff
Staff numbers
121
Tristel employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/22 21:17
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/02/25
Last earnings filing: 2019/02/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.